This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Cabergoline, an ergoline derivative, is a potent and highly specific D2 receptor agonist with a long duration of action. Controlled studies have demonstrated its effectiveness and favorable adverse effect profile in the treatment of Parkinson’s disease (PD).1 Dopamine agonists, such as apomorphine and ropinirole, increase penile erections and libido in patients with PD.2,3⇓ Recently, cabergoline induced improvement of gonadal function in hyperprolactinemic males was described,4 but cabergoline effects on penile erections and libido have not been noted.
Case report.
A 77-year-old man with a 5-year history of akinetic–rigid idiopathic PD (“on” state Unified PD Rating Scale [UPDRS]/motor subscale score, 19.5) received levodopa/benserazide up to 400 mg/day …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.